Intranasal vaccination of mice against infection with Mycobacterium tuberculosis

被引:54
作者
Falero-Diaz, G
Challacombe, S
Banerjee, D
Douce, G
Boyd, A
Ivanyi, J
机构
[1] Guys Hosp, Kings Coll, GKT Sch Med & Dent, Dept Oral Med & Pathol, London SE1 9RT, England
[2] St George Hosp, Sch Med, Dept Med Microbiol, London SW17 0RE, England
[3] Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London, England
基金
英国惠康基金;
关键词
intranasal vaccination; tuberculosis; mucosal immunity;
D O I
10.1016/S0264-410X(00)00134-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The intranasal (i.n.) route of immunisation, has recently been of active interest in endeavours to improve the efficacy of vaccination against a number of respiratory infections. Here, we examined the outcome of tuberculous infection in BALB/c mice. I.n. application of the BCG-Pasteur strain was found to be highly protective against challenge infection with the pathogenic H37Rv strain given after a 4-week interval, reflected by the 100-fold reduction of CFUs in both lungs and spleens. Vaccination with the recombinant PstS-1 antigen and cholera toxin significantly protected against the challenge given 10 days later, but only marginally after 12 weeks. Histological examination showed, that i.n. vaccination abrogated the confluent infiltration of lungs with inflammatory cells, which surrounds the granulomas in H37Rv challenged control mice. In conclusion, the strong protection demonstrated by BCG suggests that the i.n. route of vaccine delivery deserves further attention toward improving vaccination against tuberculosis. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3223 / 3229
页数:7
相关论文
共 40 条
[1]  
BARCLAY WR, 1973, AM REV RESPIR DIS, V107, P351
[2]   Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina [J].
Bergquist, C ;
Johansson, EL ;
Lagergard, T ;
Holmgren, J ;
Rudin, A .
INFECTION AND IMMUNITY, 1997, 65 (07) :2676-2684
[3]  
Berstad AKH, 1997, VACCINE, V15, P1473
[4]  
BICE DE, 1991, IMMUNOLOGY, V74, P215
[5]  
CALMETTE A., 1933, BULL ACAD MED [PARA], V110, P203
[6]  
CHENSUE SW, 1995, J IMMUNOL, V154, P5969
[7]  
Cong YZ, 1997, J IMMUNOL, V159, P5301
[8]   Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli [J].
Douce, G ;
Giuliani, MM ;
Giannelli, V ;
Pizza, MG ;
Rappuoli, R ;
Dougan, G .
VACCINE, 1998, 16 (11-12) :1065-1073
[9]  
Heritage PL, 1998, IMMUNOLOGY, V93, P249
[10]  
Hiroi T, 1998, EUR J IMMUNOL, V28, P3346, DOI 10.1002/(SICI)1521-4141(199810)28:10<3346::AID-IMMU3346>3.0.CO